<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82209">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01784848</url>
  </required_header>
  <id_info>
    <org_study_id>IEP2013_HAS</org_study_id>
    <nct_id>NCT01784848</nct_id>
  </id_info>
  <brief_title>GAstric Bypass to Treat obEse Patients With steAdy hYpertension</brief_title>
  <acronym>GATEWAY</acronym>
  <official_title>Phase 3 Randomized Controlled Trial Evaluating the Effect of Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) on Hypertension Medication Reduction, Blood Pressure Levels and Others Cardiovascular Risk Factors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital do Coracao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ethicon Endo-Surgery</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital do Coracao</source>
  <oversight_info>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an unicentric phase 3 randomized controlled trial, with allocation concealment,
      intent-to-treat analysis and mask scheme at outcome assessors level,  comparing the effect
      of Laparoscopic Roux En Y gastric bypass  with best medical treatment on reduction of
      hypertension medications prescription.

      The study hypothesis is that gastric bypass is superior than the clinical treatment on
      reduction the number of hypertension medications.

      We also evaluate the effect of Laparoscopic Roux En Y gastric bypass on systemic
      hypertension levels and others cardiovascular risk factors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>reduction of hypertension medication prescription</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reduce at least 30% of hypertension medication prescription related to the baseline hypertension treatment at 12 months after randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>reduction of hypertension medication prescription .</measure>
    <time_frame>6 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>to reduce at least 30% of hypertension medication prescription related to the baseline hypertension treatment at 6 and 24 months.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>absolute change from baseline in blood pressure levels</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>mean difference of change from baseline blood pressure levels using ambulatory blood pressure monitoring (ABPM)and using Sphygmomanometer blood pressure monitor</description>
  </other_outcome>
  <other_outcome>
    <measure>absolute change from baseline in corporeal weight and body mass index.</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>absolute change from baseline in fasting plasm glucose level</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>absolute change from baseline in HbA1c percentual</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>absolute change from baseline in insulin levels</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>absolute change from baseline in LDL-cholesterol level</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>absolute change from baseline in HDL-cholesterol level</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>absolute change from baseline in triglycerides level</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>absolute change from baseline in anthropometric measurements</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>any adverse events</measure>
    <time_frame>15 days, 1, 6, 12 and 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>all adverse reactions reported during follow-up visits.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Systemic Hypertension</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Laparoscopic Roux-en-Y gastric bypass</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laparoscopic Roux-en-Y gastric bypass is one of the techniques of bariatric surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>best hypertension clinical treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>best hypertension clinical treatment will be defined according to the principal investigator description</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic Roux-en-Y gastric bypass (LRYGB)</intervention_name>
    <description>Laparoscopic Roux-en-Y gastric bypass (LRYGB)is the one of the techniques of bariatric surgery</description>
    <arm_group_label>Laparoscopic Roux-en-Y gastric bypass</arm_group_label>
    <arm_group_label>best hypertension clinical treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged between 18 and 65 years old.

          -  hypertension diagnosis defined as in use of at least 2 high blood pressure medication
             at full doses.

          -  body mass index between 30,0 and 39,9 kg/m2.

        Exclusion Criteria:

          -  hypertension â‰¥ 180/120 mmHg;

          -  cerebrovascular diseases in the last 6 months.

          -  Cardiovascular diseases (myocardial infarction, angina, cardiac failure) in the last
             6 months.

          -  Baseline psychiatric disorders: schizophrenia, bipolar disorder, severe depression,
             psychosis.

          -  Renal diseases: diabetic nephropathy, creatinine clearance &lt; 30 ml/min.

          -  Patients with secondary hypertension except due to the sleep apnea.

          -  Advanced peripheral arterial disease

          -  atrophic gastritis

          -  Diabetes mellitus type 1 and type 2 with HbA1 c &gt;7,0%

          -  alcoholism or use of illicit drugs

          -  smokers

          -  previous laparotomy

          -  severe hepatic disorders

          -  Pregnancy or women  not using effective contraceptive methods.

          -  Recent neoplasm (&lt; 5 years)

          -  Immunosuppressant drugs

          -  Unable to understanding and follow the study protocol orientations.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Otavio Berwanger, MD, PhD</last_name>
    <phone>+5511 30536611</phone>
    <phone_ext>8201</phone_ext>
    <email>oberwanger@hcor.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Buehler, PharmD, PhD</last_name>
    <phone>+5511 30536611</phone>
    <phone_ext>8209</phone_ext>
    <email>abuehler@hcor.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Institute of Cardiac Hospital</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04005-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos A Schiavon, MD</last_name>
      <phone>+5511 98116 6666</phone>
      <email>schiavon_ca@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Anna Buehler, PharmD, PhD</last_name>
      <phone>+55 11 30536611</phone>
      <phone_ext>8209</phone_ext>
      <email>abuehler@hcor.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Carlos A Schiavon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 18, 2013</lastchanged_date>
  <firstreceived_date>February 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high blood pressure</keyword>
  <keyword>hypertension</keyword>
  <keyword>bariatric surgery</keyword>
  <keyword>Laparoscopic Roux-en-Y gastric bypass (LRYGB)</keyword>
  <keyword>obesity</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
